TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02806817

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ME-344
Description: ME-344 is a synthetic small molecule mitochondrial inhibitor based on the isoflavan ring structure. ME-344 is a chiral compound, and is manufactured predominantly as a single stereoisomer that is dextrorotatory. As a stereoisomeric drug with two chiral centers, ME-344 is one of four potential stereoisomers. The current manufacturing process produces a racemic mixture of two of those stereoisomers, which are enantiomers, and ME-344 is separated from the levorotatory enantiomer by chromatography in the final step.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab is a recombinant humanized monoclonal antibody that blocks angiogenesis by inhibiting vascular endothelial growth factor A (VEGF-A)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bevacizumab
Description: Bevacizumab is a recombinant humanized monoclonal antibody that blocks angiogenesis by inhibiting vascular endothelial growth factor A (VEGF-A)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Use saline as placebo
Study: NCT01575483

Intervention type: DRUG
Intervention: No Intervention (subjects were previously treated with Onglyza®)
Description: No Intervention
Study: NCT00825214

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Zapperclick
Description: Device deliveres small piezoelectrical discharge to bite site (forearm)

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Inactivated zapperclick device
Description: placebo
Study: NCT04620031

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK3486
Description: Loading Dose：0.1 mg/kg, infused with 4 min ± 30 s； Maintenance Dose：Maintenance is started at 0.3 mg/kg/h, and the dose can be adjusted up and down by 0.05-0.1 mg/kg/h. Range of maintenance dose: 0.06-0.8 mg/kg/h

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Loading Dose：0.5 mg/kg, infused with 4 min ± 30 s~Maintenance Dose：Maintenance is started at 1.5 mg/kg/h, and the dose can be adjusted up and down by 0.25-0.5 mg/kg/h. Range of maintenance dose:~0.3-4 mg/kg/h
Study: NCT03927222

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human CMV pp65-LAMP mRNA-pulsed autologous DCs containing GM CSF
Description: 2x10\^7 human CMV pp65-LAMP mRNA-pulsed autologous DCs are given intradermally and bilaterally at the groin site (divided equally to both inguinal regions). Patients will receive up to a total of 10 DC vaccines.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Temozolomide is a chemotherapy drug given to all enrolled patients at the post-RT clinic visit as dose-intensified TMZ (100 mg/m2/day for 21 days).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tetanus-Diphtheria Toxoid (Td)
Description: Before the first DC vaccination, patients will receive 0.5 mL of Td (tetanus and diphtheria toxoids adsorbed) intramuscularly into the deltoid muscle to ensure adequate immunity to the tetanus antigen. Prior to pp65 DC vaccination #4,(3±1) weeks after leukapheresis 2 the vaccine site will receive a pre-conditioning intradermal injection of Td (1 flocculation unit (Lf), in 0.3 mL of saline for a total of 0.4 mL).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: Granulocyte macrophage-colony stimulating factor (GM-CSF) is a sterile, white, preservative-free lyophilized powder in a vial containing 250 mcg that will be reconstituted in 0.5 mL of sterile water for injection and used as an adjuvant with the DC vaccine.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 111-Indium-labeling of Cells for in vivo Trafficking Studies
Description: 111-In-labeled DCs are 2 x 10\^7 pp65-LAMP mRNA loaded mature DCs labeled with 111-In (50 μCi / 5 x 10\^7 DCs) and given i.d. as the fourth vaccine. In up to 16 patients, the fourth vaccine will be labeled with 111-In (50 μCi / 5 x 10\^7 DCs) prior to injection.
Study: NCT02836054

Intervention type: PROCEDURE
Group type: OTHER
Intervention: lumbar puncture (LP)

Intervention type: PROCEDURE
Group type: OTHER
Intervention: lumbar puncture (LP)

Intervention type: PROCEDURE
Group type: OTHER
Intervention: brain MRI

Intervention type: PROCEDURE
Group type: OTHER
Intervention: brain MRI
Study: NCT03828877

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group A ( Group Acupuncture)
Description: Group A; Acupunctur will be done with Pres Needle (0.22x1.5 mm).Acupuncture will be done points fo SP 6, LI 4 , ST 36 , LİV 3, LU 9 ,LU 7.
Study: NCT04440930

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: White tea
Description: Mouthwash with white tea five to six times a day for nine weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Salt water with soda
Description: Mouthwash with salt water and soda eight to ten times a day for nine weeks
Study: NCT00815347

Intervention type: DRUG
Group type: OTHER
Intervention: bosentan
Description: Bosentan 62.5mg or placebo orally, twice a day for four weeks. After four weeks at this dose the subjects will have an increase to bosentan 125 mg or placebo orally twice daily for another four weeks. At week eight, subjects will crossover to bosentan or placebo depending upon their first randomization.

Intervention type: DRUG
Group type: OTHER
Intervention: placebo
Description: Bosentan 62.5mg or placebo orally, twice a day for four weeks. After four weeks at this dose the subjects will have an increase to bosentan 125 mg or placebo orally twice daily for another four weeks. At week eight, subjects will crossover to bosentan or placebo depending upon their first randomization.
Study: NCT03549988

Intervention type: OTHER
Intervention: Fecal Calprotectin (FC) measurements with IBDocTM
Description: Each IBDocTM kit measure one fecal calprotectin value. The IBDoc® is an in-vitro diagnostic immunoassay analyzed by a downloadable smartphone application (CalApp®). A patient is able to process their stool at home using a test cassette.~The IBDocTM test results are displayed in a light signal system as three titre categories; normal \<100 µg/g (green), 100-300 µg/g (yellow), \>300 µg/g (high). Patients' results will be sent directly to the central research coordinator through the IBDoc® Web Portal. If the FC is \>250 µg/g a second FC will be performed within 2 weeks. If this result is \<250 µg/g patients will continue to monitor their FC every 2 months. If the second result is \>250 µg/g, the attending physician will review the patient either by telephone or in the office within 7 days.
Study: NCT01554293

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo
Description: Matching Placebo, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBL 1427 capsules
Description: PBL 1427 capsules 20 mg and 150 mg, single dose
Study: NCT01260207

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IVR group
Description: Patients in this arm will receive IVR follow-up telephone calls at 1,3,6,9 and 12 months post-discharge consisting of predetermined questions related to medication management, smoking cessation, diet, exercise and education as recommended by the ACC/AHA BPG for ACS. Upon completion of the IVR follow-up, all patients will be called by a member of the clinical research staff and asked to complete a follow-up survey.
Study: NCT02014051

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SyB C-1101
Description: SyB C-1101（rigosertib sodium） will be administered to two cohorts at either 280 mg/day or 560 mg/day.~The dose will be administered orally twice daily for 14 consecutive days, followed by 7-day observation period. The treatment period of 21 days (14 days of administration + 7 days of observation) constitutes 1 cycle.~The study will involve treatment through the second cycle, but treatment can be continued for 3 or more cycles if conditions for continued administration are satisfied. However, treatment will be limited to a maximum of 6 cycles including the first cycle.
Study: NCT03669718

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ISA101b
Description: Every 3 weeks for a total of 3 times

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: Every 3 weeks for up to 24 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cemiplimab
Description: Every 3 weeks for up to 24 months

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Every 3 weeks for a total of 3 times
Study: NCT02570334

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIV-infected children initiated antiretroviral treatment within the first 7 months of life
Description: All arms will recieve a thourough clinical evaluation : Global motor development (Touwen test), global cognitive development (K-ABC II test), visual (Log Mar Char) and hearing (full ear nose and throat examination) impediments as well as a questionnaire concerning socioeconomic situation, medical history of the child and mother, and HIV treatment and follow up information.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIV-infected children initiated antiretroviral treatment within the first 7 months of life
Description: All arms will recieve a thourough clinical evaluation : Global motor development (Touwen test), global cognitive development (K-ABC II test), visual (Log Mar Char) and hearing (full ear nose and throat examination) impediments as well as a questionnaire concerning socioeconomic situation, medical history of the child and mother, and HIV treatment and follow up information.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIV-infected children initiated antiretroviral treatment within the first 7 months of life
Description: All arms will recieve a thourough clinical evaluation : Global motor development (Touwen test), global cognitive development (K-ABC II test), visual (Log Mar Char) and hearing (full ear nose and throat examination) impediments as well as a questionnaire concerning socioeconomic situation, medical history of the child and mother, and HIV treatment and follow up information.
Study: NCT00109876

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography-Guided Optical Sensor-Guided Radiofrequency Ablation
Description: Undergo RFA
Study: NCT03452241

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention Group
Description: The medical staffs who received the training will use the manual of brief intervention to deliver BI and other materials about the harm of substance use.BI refers to a standard 15-30 minute intervention that includes a series of standard models that stimulate knowledge, motivation and behavior that reduce substance abuse.the harm of substance use is a dedicated paper publicity handbook, written by the SHMC, detailing the hazards of substance abuse.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention Group
Description: The medical staffs who received the training will use the manual of brief intervention to deliver BI and other materials about the harm of substance use.BI refers to a standard 15-30 minute intervention that includes a series of standard models that stimulate knowledge, motivation and behavior that reduce substance abuse.the harm of substance use is a dedicated paper publicity handbook, written by the SHMC, detailing the hazards of substance abuse.

Intervention type: OTHER
Group type: OTHER
Intervention: Control Group
Description: The participants only receive the materials about the harm of substance use.the harm of substance use is a dedicated paper publicity handbook, written by the SHMC, detailing the hazards of substance abuse.
Study: NCT01520194

Intervention type: OTHER
Intervention: women attending reproductive health clinics
Description: women visiting BEMFAM´s clinics from January 2012 until Narch 2013 filled a self-administered questionnaire based on psychometric scale developes by Zhu TC et al

Intervention type: OTHER
Intervention: medical records
Description: medical chart review of patients assisted January 2009 to December 2010
Study: NCT02271399

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: acetylsalicylic acid
Description: 300 mg aspirin(acetylsalicylic acid, AA, Bayer)/day was given orally for 10 days postoperatively.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rivaroxaban
Description: xarelto 10mg(rivaroxaban, AA, Bayer)/day was given orally for 10 days postoperatively
Study: NCT02107573

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rotator Cuff Repair without Suprascapular Nerve decompression
Description: Traditional rotator cuff repair without Suprascapular nerve decompression

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rotator Cuff Repair with Suprascapular Nerve decompression
Description: Traditional rotator cuff repair with Suprascapular nerve decompression
Study: NCT00866918

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arsenic Trioxide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arsenic Trioxide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IT or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IT or IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diagnostic Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diagnostic Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mercaptopurine
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mercaptopurine
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tretinoin
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tretinoin
Description: Given orally
Study: NCT04760197

Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study: NCT00511797

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SH T04740B
Description: Drospirenone 1mg/EE 20µg (ß-CDC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SH T00186DF
Description: Drospirenone 3 mg/EE 20µg (ß-CDC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SH T04740F
Description: Drospirenone 2 mg/EE 20µg (ß-CDC)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03989583

Intervention type: OTHER
Intervention: Infrared thermography
Description: Temperature observation in foot and footwear in healthy children
Study: NCT03128541

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound spine
Description: A ultrasound of the lumbar spine of each patient will be performed in both positions to identify vertebral levels

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound spine
Description: A ultrasound of the lumbar spine of each patient will be performed in both positions to identify vertebral levels
Study: NCT01121913

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trazodone HCl
Description: The dosage of trazodone.HCl during this treatment phase was a single oral dose of 300 mg (one CR tablet) at 07:30 (after an overnight fast of at least 10 hours) on clinic days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trazodone HCl
Description: The dosage of trazodone.HCl during this treatment phase was a single oral dose of 300 mg (one CR tablet) at 07:30 (after an overnight fast of at least 10 hours) on clinic days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trazodone HCl
Description: The dosage of trazodone.HCl during this treatment phase was 2 oral doses of 150 mg each: one controlled-release (CR) tablet at 07:30 (after an overnight fast of at least 10 hours) and 19:30 (after a fast of at least 2 hours) on clinic days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trazodone HCl
Description: The dosage of trazodone.HCl during this treatment phase was three oral doses of 100 mg each: one immediate-release (IR) tablet at 07:30 (after an overnight fast of at least 10 hours), 15:30 and 23:30 (both dosages after a fast of at least 2 hours) on clinic days.
Study: NCT03230409

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Leaflet written in the patient's/family mother tongue
Description: At baseline visit, the parents or carers of the children and/or the young patients themselves (in the case of adolescents \>12 years of age), were given a leaflet including questions and answers about the most common doubts that people have about anti-TB treatment (what to do if you forget a dose, if you vomit, if you have stomach ache, etc.). The study nurse read and reviewed the leaflet with the family. This leaflet was available in 10 different languages: Spanish and Catalan (the two official languages of the country), English, French, German, Russian, Romanian, Chinese, Urdu and Arabic.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A follow-up telephone call
Description: A follow-up open telephone call was made 7-10 days after the baseline visit and whenever the patient failed to attend the scheduled visits. The parents and/or patient were informed about this. This call was made to reinforce the information, answer any questions that may have arisen and insist on the importance of proper follow-up.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Eidus-Hamilton Test
Description: E-H test was performed twice, 2 weeks after the baseline visit and at the end of treatment. To prevent patients from only taking their medication occasionally, directly before their visits, they were not informed of the purpose of the urine test. This test is a rapid, simple point-of-care method to detect urinary acetyl-isoniazid, the main metabolite of isoniazid, up to 12-24 hours following isoniazid administration and is used as a surrogate marker of treatment adherence. The test consists of placing 4 drops of a 10%potassium cyanide solution and 9 drops of a 10%chloramine solution in a test tube containing 4 drops of patient urine. The result is considered positive if a deep red color develops after 1 minute. If a pink color slowly appears,this indicates that there are only traces of the metabolite. If there is no change in color, the result is considered negative and suggests no recent isoniazid intake. The sensitivity and specificity of this test have been reported to be over 99%

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A written questionnaire
Description: The parents or carers of the children and/or the young patients themselves were asked to complete a written questionnaire about adherence to anti-TB treatment on all the follow-up visits, which was partially adapted from two validated questionnaires on adherence to chronic therapies (SMAQ compliance test, Svarstad et al., 1999; and Hermes test, Rodríguez-Chamorro et al., 2008).
Study: NCT00056329

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin E
Description: 1,000 international units twice daily for three years

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: multivitamin
Description: once daily for three years

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: multivitamin
Description: once daily for three years

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo twice daily for three years
Study: NCT04643964

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Entrée: Cognitive skills
Description: In this condition, participants view a video-based intervention covering cognitive emotion regulation skills. This intervention asks participants to respond to questions and practice identifying and evaluating their own thoughts using an intervention worksheet. One week after the intervention, participants are asked to upload a worksheet showing their efforts to use the intervention skills.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Entrée: Behavioral skills
Description: In this condition, participants view a video-based intervention covering behavioral emotion regulation skills. This intervention asks participants to respond to questions and practice scheduling activities that might give them a sense of pleasure or accomplishment using an intervention worksheet. One week after the intervention, participants are asked to upload a worksheet showing their efforts to schedule and engage in behaviors in line with the intervention skills.
Study: NCT00854152

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0980
Description: Escalating repeating dose
Study: NCT04237675

Intervention type: PROCEDURE
Intervention: surgery and anesthesia
Description: patients with MS who received general or regional anesthesia for a surgery or labor

Intervention type: PROCEDURE
Intervention: surgery and anesthesia
Description: patients with MS who received general or regional anesthesia for a surgery or labor
Study: NCT02413593

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDV/SOF
Description: 90/400 mg FDC tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: Tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
Study: NCT04643964

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Entrée: Interpersonal skills
Description: In this condition, participants view a video-based intervention covering interpersonal emotion regulation skills. This intervention asks participants to respond to questions and practice communicating effectively using an intervention worksheet. One week after the intervention, participants are asked to upload a worksheet showing their efforts to use the intervention skills.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sampler skills
Description: In this condition, participants view a video-based intervention covering three emotion regulation skills: cognitive, behavioral, and interpersonal skills. This intervention asks participants to respond to questions and practice using skills using intervention worksheets. One week after the intervention, participants are asked to upload a worksheet showing their efforts to use the intervention skills.
Study: NCT03207074

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: iKnife i.e. Rapid Evaporative Ionisation Mass Spectrometry
Description: The endometrial tissue will be analysed by this new technology and compared to gold standard (histopathology)
Study: NCT03631719

Intervention type: BIOLOGICAL
Intervention: Wolbachia-carrying Ae.aegypti mosquitoes
Description: Wolbachia-infected Ae. aegypti mosquito eggs and adults sequentially deployed into Medellin and Bello, Colombia. Deployments cease once Wolbachia prevalence has reached a predetermined frequency (usually ≥60%).